Lab Reig Jofre

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Lab Reig Jofre has already paid €0.024 in dividends. The last payout was in June.

Financials

In the last quarter, Lab Reig Jofre had revenue of €82.17m and net profit of €375k

(EUR)	June 2026	YoY
Revenue	82.17m	1.10%
Gross profit	18.51m	61.64%
Net profit	375k	117.64%
EBITDA	8m	86.61%

Fundamentals

Metric	Value
Market capitalization	€214.22m
Number of shares	82.08m
52-week high/low	€2.94 - €2.32
Dividend yield	0.92%
Dividends TTM	€0.024
Beta	0.94
P/E ratio	30.81
PEG ratio	-1.34
P/B ratio	0.97
P/S ratio	0.64

Company profile

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.